These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36715049)

  • 1. Changing epidemiology of dengue fever in children in South America.
    Fonseca SNS
    Curr Opin Pediatr; 2023 Apr; 35(2):147-154. PubMed ID: 36715049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of epidemic dengue/dengue hemorrhagic fever as a public health problem in the Americas.
    Gubler DJ; Trent DW
    Infect Agents Dis; 1993 Dec; 2(6):383-93. PubMed ID: 8012739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue vaccine supplies under endemic and epidemic conditions in three dengue-endemic countries: Colombia, Thailand, and Vietnam.
    Lee JS; Lim JK; Dang DA; Nguyen THA; Farlow A
    Vaccine; 2017 Dec; 35(50):6957-6966. PubMed ID: 29110932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for a dengue virus vaccine.
    Whitehead SS; Blaney JE; Durbin AP; Murphy BR
    Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling dengue with vaccines in Thailand.
    Chao DL; Halstead SB; Halloran ME; Longini IM
    PLoS Negl Trop Dis; 2012; 6(10):e1876. PubMed ID: 23145197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
    Biswal S; Reynales H; Saez-Llorens X; Lopez P; Borja-Tabora C; Kosalaraksa P; Sirivichayakul C; Watanaveeradej V; Rivera L; Espinoza F; Fernando L; Dietze R; Luz K; Venâncio da Cunha R; Jimeno J; López-Medina E; Borkowski A; Brose M; Rauscher M; LeFevre I; Bizjajeva S; Bravo L; Wallace D;
    N Engl J Med; 2019 Nov; 381(21):2009-2019. PubMed ID: 31693803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?
    Gubler DJ
    Comp Immunol Microbiol Infect Dis; 2004 Sep; 27(5):319-30. PubMed ID: 15225982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets and strategies for vaccine development against dengue viruses.
    Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating dengue burden in Africa in passive fever surveillance and seroprevalence studies: protocol of field studies of the Dengue Vaccine Initiative.
    Lim JK; Carabali M; Lee JS; Lee KS; Namkung S; Lim SK; Ridde V; Fernandes J; Lell B; Matendechero SH; Esen M; Andia E; Oyembo N; Barro A; Bonnet E; Njenga SM; Agnandji ST; Yaro S; Alexander N; Yoon IK
    BMJ Open; 2018 Jan; 8(1):e017673. PubMed ID: 29358421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DengueTools: innovative tools and strategies for the surveillance and control of dengue.
    Wilder-Smith A; Renhorn KE; Tissera H; Abu Bakar S; Alphey L; Kittayapong P; Lindsay S; Logan J; Hatz C; Reiter P; Rocklöv J; Byass P; Louis VR; Tozan Y; Massad E; Tenorio A; Lagneau C; L'Ambert G; Brooks D; Wegerdt J; Gubler D
    Glob Health Action; 2012; 5():. PubMed ID: 22451836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective and immunological behavior of chimeric yellow fever dengue vaccine.
    Halstead SB; Russell PK
    Vaccine; 2016 Mar; 34(14):1643-7. PubMed ID: 26873054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dengue vaccines. A reality for Argentina?].
    Orellano PW; Salomón OD
    Medicina (B Aires); 2016; 76(2):98-102. PubMed ID: 27028058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine.
    Godói IP; Da Silva LVD; Sarker AR; Megiddo I; Morton A; Godman B; Alvarez-Madrazo S; Bennie M; Guerra-Junior AA
    Expert Rev Vaccines; 2018 Dec; 17(12):1123-1133. PubMed ID: 30417706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America.
    Sarti E; L'Azou M; Mercado M; Kuri P; Siqueira JB; Solis E; Noriega F; Ochiai RL
    Int J Infect Dis; 2016 Mar; 44():44-9. PubMed ID: 26836763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.